A recent study (44) has found that hs-CRP and low-density lipoprotein cholesterol can predict the likelihood of CV events and death, and the risk of atherosclerosis can be reduced through active combination of lipid-lowering and anti-inflammatory therapy. This evidence concerns the gene CRP and atherosclerosis.